Stockscreener 앱 받기
31.18
2.55%
0.775
시장 영업 전:
31.30
0.12
+0.38%
전일 마감가:
$30.41
열려 있는:
$30.4
하루 거래량:
883.67K
Relative Volume:
1.08
시가총액:
$3.58B
수익:
$14.09M
순이익/손실:
$-176.94M
주가수익비율:
-14.50
EPS:
-2.15
순현금흐름:
$-141.24M
1주 성능:
-10.94%
1개월 성능:
-5.46%
6개월 성능:
+21.51%
1년 성능:
+45.02%
1일 변동 폭
$30.12
$31.59
1주일 범위
$30.12
$35.71
52주 변동 폭
$14.06
$42.00
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
명칭
Newamsterdam Pharma Company Nv
전화
35 206 2971
주소
GOOIMEER 2-35, NARRDEN
Compare NAMS vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
31.18 | 3.50B | 14.09M | -176.94M | -141.24M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-20 | 재개 | H.C. Wainwright | Buy |
| 2025-08-25 | 개시 | Wells Fargo | Overweight |
| 2025-07-17 | 개시 | Goldman | Neutral |
| 2025-06-17 | 개시 | Citigroup | Buy |
| 2025-06-10 | 개시 | Stifel | Buy |
| 2025-06-04 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-05-15 | 개시 | TD Cowen | Buy |
| 2024-03-14 | 개시 | Scotiabank | Sector Outperform |
| 2024-01-18 | 개시 | Guggenheim | Buy |
| 2024-01-16 | 개시 | Piper Sandler | Overweight |
| 2023-10-30 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Newamsterdam Pharma Company Nv 주식(NAMS)의 최신 뉴스
NewAmsterdam Pharma Hits Day Low at $30.20 Amid Price Pressure - Markets Mojo
NewAmsterdam Pharma (NAMS) Stock Analysis: Exploring a 46.68% Potential Upside Amidst Strong Buy Ratings - DirectorsTalk Interviews
NewAmsterdam Pharma (NASDAQ:NAMS) CEO Sells $14,753,257.75 in Stock - MarketBeat
NewAmsterdam Pharma CEO Sells Over $14 Million in Shares - TradingView
NewAmsterdam Pharma (NAMS) CEO sells 443,707 shares after option exercise - Stock Titan
NewAmsterdam Pharma (NASDAQ: NAMS) files Form 144 to sell 443,707 shares - Stock Titan
NewAmsterdam Pharma (NASDAQ:NAMS) Sees Large Volume IncreaseStill a Buy? - MarketBeat
NewAmsterdam Highlights Obicetrapib Progress in Investor Presentation - TipRanks
NewAmsterdam posts updated investor presentation highlighting obicetrapib efficacy, safety, IP and cash runway - TradingView
Obicetrapib data and AD signals in NewAmsterdam (NAMS) deck - Stock Titan
Handelsbanken Fonder AB Boosts Stake in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March - Sahm
JPMorgan Chase & Co. Has $37.04 Million Position in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) CEO Sells 58,253 Shares of Stock - MarketBeat
NewAmsterdam Pharma (NAMS) CEO exercises options and sells 306,293 shares - Stock Titan
Liquidity Mapping Around (NAMS) Price Events - Stock Traders Daily
Rate Hike: Is NewAmsterdam Pharma Company NV stock overvalued or fairly pricedJuly 2025 Intraday Action & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Heart drug developer NewAmsterdam opens March investor webcasts - Stock Titan
NAMS Stock Price and Chart — NASDAQ:NAMS - TradingView
NewAmsterdam Pharma (NAMS) Stock Analysis: A Biotech Play with 34.71% Upside Potential - DirectorsTalk Interviews
Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) Insider Sells 45,481 Shares of Stock - MarketBeat
NewAmsterdam Pharma CSO Sells Shares - TradingView
NewAmsterdam Pharma (NAMS) CSO executes 45,481-share stock sale - Stock Titan
[144] NewAmsterdam Pharma Co N.V. SEC Filing - Stock Titan
The Bull Case For NewAmsterdam Pharma (NAMS) Could Change Following Obicetrapib-Focused 2025 Results And Share Shelf Filing - simplywall.st
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
NAMS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Q1 Earnings Forecast for NAMS Issued By HC Wainwright - MarketBeat
Published on: 2026-02-22 03:05:00 - baoquankhu1.vn
Can NewAmsterdam Pharma Company N.V. Equity Warrant stock beat analyst upgradesGap Up & Reliable Volume Spike Alerts - mfd.ru
What is HC Wainwright's Estimate for NAMS Q3 Earnings? - MarketBeat
6,000‑Share Rule 144 Sale by NewAmsterdam Pharma (NASDAQ: NAMS) - Stock Titan
Cantor Fitzgerald Maintains Overweight on NAMS NewAmsterdam Pharma Feb 2026 - Meyka
Cantor Fitzgerald reiterates NewAmsterdam Pharma stock rating at Overweight - Investing.com Nigeria
Guggenheim raises NewAmsterdam Pharma stock price target on EU launch timing - Investing.com Nigeria
Cantor Fitzgerald reiterates NewAmsterdam Pharma stock rating at Overweight By Investing.com - Investing.com Australia
Readystate Asset Management LP Sells 196,841 Shares of NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
Ideas Watch: What are NewAmsterdam Pharma Company NVs technical support levels2025 Growth vs Value & Step-by-Step Swing Trade Plans - baoquankhu1.vn
Aberdeen Group plc Has $18.83 Million Stock Holdings in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
Needham & Company LLC Issues Positive Forecast for NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price - Defense World
Decoding NewAmsterdam Pharma Co NV (NAMS): A Strategic SWOT Insi - GuruFocus
Forecasting The Future: 4 Analyst Projections For NewAmsterdam Pharma Co - Benzinga
Earnings Summary: NewAmsterdam Pharma Co Q4 - Benzinga
NewAmsterdam Pharma Narrows Net Loss in 2025, Revenue Drops - marketscreener.com
NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update - The Manila Times
NewAmsterdam Pharma Co N.V. SEC 10-K Report - TradingView
NAMS: 2025 revenue dropped 51% to $22.5M; net loss improved to $203.8M; cash reserves at $728.9M - TradingView
NewAmsterdam Pharma (NAMS) Stock Analysis: Potential 41% Upside Beckons Investors Despite Current Challenges - DirectorsTalk Interviews
Published on: 2026-02-17 13:42:01 - mfd.ru
Viking Global discloses 3.7% NewAmsterdam Pharma (NAMS) holding in 13G/A - Stock Titan
NewAmsterdam Pharma Company N.V. $NAMS Shares Sold by TimesSquare Capital Management LLC - MarketBeat
Newamsterdam Pharma Company Nv (NAMS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.11%
6.00%
자본화:
|
볼륨(24시간):